Kura Oncology (KURA) Q3 FY2026 earnings: revenue $23 million, up 10.1% on the year
Kura Oncology, Inc. (KURA) reported revenue of $23 million for Q3 FY2026, the quarter ended 30 September 2026, up 10.1% on the same quarter a year earlier. Net income was -$70 million, and diluted earnings per share $-0.78. The figures are the company's own, from the 10-Q it filed with the SEC on 10 November 2026.
Revenue
$23 million
+10.1% on the year · +9.4% on the quarter
Q1 FY2025Q3 FY2026
Operating margin
-326.9%
-385.5% a year earlier
Q1 FY2025Q3 FY2026
Net income
-$70 million
Q1 FY2025Q3 FY2026
Diluted EPS
-$0.78
Q1 FY2025Q3 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 1 new, 6 kept.
KOMZIFTI net product revenue rose 53%: Net product revenue was $13.9 million, up 53% from $9.1 million in second quarter 2026. This was the first quarter with product revenue compared with none a year earlier.
New patient starts up 30%: About 150 new patient starts were recorded, up 30% from second quarter 2026. Management described new patient starts as a key indicator of physician preference.
Majority share of new patient starts kept: KOMZIFTI kept a majority share of new patient starts in the relapsed or refractory NPM1-mutated AML menin inhibitor class.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
-54.4
-62.5
-80.6
Capital expenditure
0.4
0.7
2.6
-32.2%
-82.7%
Free cash flow
-54.9
-63.2
-83.2
Free cash flow margin
-240.3%
-302.8%
-400.9%
Cash from investing
9.6
92.2
94.0
-89.6%
-89.8%
Cash from financing
32.5
1.5
0.0
+2,071.0%
Depreciation
0.3
0.4
0.2
-10.8%
+100.6%
Share-based compensation
8.2
8.2
11.0
-0.5%
-25.5%
Diluted shares, weighted
90m
89m
88m
+1.1%
+2.5%
Shares outstanding at period end
92m
89m
87m
+3.3%
+5.6%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
18.0
48.4
243
-62.9%
-92.6%
Debt
9.8
9.8
9.7
+0.4%
+1.7%
Operating lease liabilities
14.1
13.4
8.4
+5.6%
+68.8%
Other liabilities
525
516
389
+1.6%
+34.9%
Total liabilities and equity
566
588
649
-3.6%
-12.8%
Fixed assets
7.5
7.6
7.4
-1.7%
+0.8%
Investments
434
449
454
-3.3%
-4.4%
Cash and equivalents
57.9
70.2
95.3
-17.5%
-39.2%
Receivables
14.5
9.4
35.9
+53.3%
-59.7%
Inventory
5.0
2.5
n/a
+100.5%
Other assets
47.5
49.2
56.4
-3.6%
-15.8%
Total assets
566
588
649
-3.6%
-12.8%
Questions
What was Kura Oncology's revenue in Q3 FY2026?
Kura Oncology (KURA) reported revenue of $23 million for Q3 FY2026, the quarter ended 30 September 2026, up 10.1% on the same quarter a year earlier.
How much did Kura Oncology earn in Q3 FY2026?
Net loss for Q3 FY2026 was $70 million, and the diluted loss per share $0.78.
When did Kura Oncology report Q3 FY2026 results?
Kura Oncology filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 10 November 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2026, filed 10 November 2026: the filing.